Conformation-dependent phosphorylation of p53.

Phosphorylation of the p53 tumor suppressor protein is known to modulate its functions. Using bacterially produced glutathione S-transferase (GST)-p53 fusion protein and baculovirus-expressed histidine-tagged p53 ((His)p53), we have determined human p53 phosphorylation by purified forms of jun-N-kinase (JNK), protein kinase A (PKA), and beta subunit of casein kinase II (CKIIbeta) as well as by kinases present in whole cell extracts (WCEs). We demonstrate that PKA is potent p53 kinase, albeit, in a conformation- and concentration-dependent manner, as concluded by comparing full-length with truncated forms of p53. We further demonstrate JNK interaction with GST-p53 and the ability of JNK to phosphorylate truncated forms of GST-p53 or full-length (His)p53. Dependence of phosphorylation on conformation of p53 is further supported by the finding that the wild-type form of p53 (p53wt) undergoes better phosphorylation by CKIIbeta and by WCE kinases than mutant forms of p53 at amino acid 249 (p53(249)) or 273 (p53(273)). Moreover, shifting the kinase reaction's temperature from 37 degrees C to 18 degrees C reduces the phosphorylation of mutant p53 to a greater extent than of p53wt. Comparing truncated forms of p53 revealed that the ability of CKIIbeta, PKA, or WCE kinases to phosphorylate p53 requires amino acids 97-155 within the DNA-binding domain region. Among three 20-aa peptides spanning this region we have identified residues 97-117 that increase p53 phosphorylation by CKIIbeta while inhibiting p53 phosphorylation by PKA or WCE kinases. The importance of this region is further supported by computer modeling studies, which demonstrated that mutant p53(249) exhibits significant changes to the conformation of p53 within amino acids 97-117. In summary, phosphorylation-related analysis of different p53 forms in vitro indicates that conformation of p53 is a key determinant in its availability as a substrate for different kinases, as for the phosphorylation pattern generated by the same kinase.

[1]  C. Harris,et al.  Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. , 1996, Journal of the National Cancer Institute.

[2]  C. Prives,et al.  Regulation of Mutant p53 Temperature-sensitive DNA Binding* , 1996, The Journal of Biological Chemistry.

[3]  J. Lord,et al.  Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate. , 1996, Oncogene.

[4]  C. Harris,et al.  The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. , 1996, Genes & development.

[5]  M. Pincus,et al.  Conformational effects in the p53 protein of mutations induced during chemical carcinogenesis: Molecular dynamic and immunologic analyses , 1996, Journal of protein chemistry.

[6]  E. Paley.  CANCER BIOLOGY: Phosphorylation of T antigen and p53 in carcinogen-treated SV40-transformed Chinese hamster cells , 1996 .

[7]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[8]  D. Meek,et al.  Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. , 1996, Nucleic acids research.

[9]  V. Adler,et al.  UV Irradiation and Heat Shock Mediate JNK Activation via Alternate Pathways (*) , 1995, The Journal of Biological Chemistry.

[10]  P. Tegtmeyer,et al.  The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Prives,et al.  Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases , 1995, Nature.

[12]  K. Scheidtmann,et al.  p53 phosphorylation mutants retain transcription activity. , 1995, Oncogene.

[13]  M. Oren,et al.  Biochemical properties and biological effects of p53. , 1995, Current opinion in genetics & development.

[14]  K. Vousden,et al.  Transcriptional activation by p53 correlates with suppression of growth but not transformation , 1994, Cell.

[15]  M. Fiscella,et al.  The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. , 1994, Oncogene.

[16]  D. Beach,et al.  Cyclin G is a transcriptional target of the p53 tumor suppressor protein. , 1994, The EMBO journal.

[17]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[18]  M. Pincus,et al.  Interaction between cytochrome P450 2B1 and cytochrome bs: inhibition by synthetic peptides indicates a role for P450 residues Lys-122 and Arg-125. , 1994, Biochemical and biophysical research communications.

[19]  A. Levine,et al.  p53 and E2F-1 cooperate to mediate apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[21]  L. Donehower,et al.  The tumore suppressor p53 , 1993 .

[22]  D. Lane,et al.  Activation of the cryptic DNA binding function of mutant forms of p53. , 1993, Nucleic acids research.

[23]  B. Stillman,et al.  Analysis of a protein-binding domain of p53 , 1993, Molecular and cellular biology.

[24]  D. Grunwald,et al.  Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S100b-binding protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[26]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[27]  K. Sakaguchi,et al.  Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53 , 1992, Molecular and cellular biology.

[28]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Meek,et al.  Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme. , 1992, Oncogene.

[30]  A. Kraft,et al.  Phorbol esters stimulate the phosphorylation of c-Jun but not v-Jun: regulation by the N-terminal delta domain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[32]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[33]  D. Meek,et al.  The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II. , 1990, The EMBO journal.

[34]  P. Friedman,et al.  Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Scheraga,et al.  On the multiple‐minima problem in the conformational analysis of polypeptides. II. An electrostatically driven Monte Carlo method—tests on poly(L‐alanine) , 1988, Biopolymers.

[36]  H. Scheraga,et al.  Energy parameters in polypeptides. 9. Updating of geometrical parameters, nonbonded interactions, and hydrogen bond interactions for the naturally occurring amino acids , 1983 .